NCT06131983 - Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Facio-Scapulo-Humeral Dystrophy

Interventions

DRUG

ARO-DUX4 for Injection

single or multiple doses of ARO-DUX4 by intravenous (IV) infusion

DRUG

Placebo

calculated volume to match active treatment by IV infusion

Trial Locations (17)

1010

RECRUITING

Research Site 1, Auckland

2170

RECRUITING

Research Site 2, Liverpool

2333

RECRUITING

Research Site 1, Leiden

3004

RECRUITING

Research Site 4, Melbourne

4066

RECRUITING

Research Site 3, Auchenflower

4575

RECRUITING

Research Site 1, Birtinya

10700

WITHDRAWN

Research Site, Bangkok

20162

RECRUITING

Research Site 1, Milan

28034

RECRUITING

Research Site 2, Madrid

46026

RECRUITING

Research Site 1, Valencia

80336

RECRUITING

Research Site 2, München

89081

RECRUITING

Research Site 1, Ulm

T2N4Z6

NOT_YET_RECRUITING

Research Site 2, Calgary

T6G2G4

RECRUITING

Research Site 3, Edmonton

H3A2B4

RECRUITING

Research Site 1, Montreal

00168

RECRUITING

Research Site 2, Roma

08035

RECRUITING

Research Site 3, Barcelona